Ceftaroline News and Research

RSS
Forest Laboratories' ceftaroline fosamil receives FDA Advisory Committee approval for CABP and cSSSI

Forest Laboratories' ceftaroline fosamil receives FDA Advisory Committee approval for CABP and cSSSI

Fidaxomicin, CDA1/CDB1 effective for treating CDI : Report

Fidaxomicin, CDA1/CDB1 effective for treating CDI : Report

Forest Laboratories' fourth-quarter net sales up 11.0% to $995.6M

Forest Laboratories' fourth-quarter net sales up 11.0% to $995.6M

Bactericidal antibiotic with activity against MRSA for treatment of cSSSIs would earn 25% patient share: Report

Bactericidal antibiotic with activity against MRSA for treatment of cSSSIs would earn 25% patient share: Report

Delay in Vibativ's approval for nosocomial pneumonia to reduce previously forecasted commercial impact

Delay in Vibativ's approval for nosocomial pneumonia to reduce previously forecasted commercial impact

Forest Laboratories acquires additional rights to NXL 104 beta-lactamase inhibitor

Forest Laboratories acquires additional rights to NXL 104 beta-lactamase inhibitor

AstraZeneca signs definitive agreement to acquire Novexel

AstraZeneca signs definitive agreement to acquire Novexel

MRSA, the most concerning pathogen to surveyed for skin and skin structure infections

MRSA, the most concerning pathogen to surveyed for skin and skin structure infections

Report on the community-acquired pneumonia drug market

Report on the community-acquired pneumonia drug market

Leading driver of antibiotic selection in nosocomial pneumonia in Europe found

Leading driver of antibiotic selection in nosocomial pneumonia in Europe found

Novexel commences comparative study of NXL103 to oral linezolid

Novexel commences comparative study of NXL103 to oral linezolid

FOCUS 1 and FOCUS 2 clinical trial results released

FOCUS 1 and FOCUS 2 clinical trial results released

Forest Labs and Astrazeneca to co-develop and commercialize ceftaroline

Forest Labs and Astrazeneca to co-develop and commercialize ceftaroline